Lv71
3234 积分 2021-10-12 加入
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
4小时前
已完结
Simplifying the concept of level of evidence in lay language for all aspects of learners: In brief review
9小时前
已关闭
GnRH blockers: a changing paradigm in the management of prostate cancer
6天前
已完结
The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer
11天前
已完结
Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy
19天前
已关闭
Pericyte Loss in Diabetic Retinopathy: Mechanisms and Consequences
19天前
已完结
Mitigating acute chemotherapy-associated adverse events in patients with cancer
1个月前
已完结
MA06.04 Unecritinib in Patients with ROS1 Positive Advanced Non-Small Cell Lung Cancer: Updated Results from a Phase II Trial
1个月前
已完结
First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes
1个月前
已关闭
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
2个月前
已完结
皖公网安备34019202002308
